Global Alzheimer’s Disease Diagnostic Market Size, Share, Forecast Report, 2020-2027

Alzheimer’s is a type of dementia which results in memory loss accompanied by problem in thinking and behavior process. Alzheimer's is a progressive disease as it gradually increases with time and damages maximum part of the brain finally destroying brain cells. It has been observed that maximum incidence of this disease is in UK where more than 520,000 people are diagnosed with Alzheimer's disease and the increasing ageing population is the reason which is driving Alzheimer’s disease diagnostic and therapeutic market.

The Global Alzheimer’s Disease Diagnostic Market for this is expected to reach USD 12 billion by the end of the forecasted period growing at a CAGR of 10%.
Key Players for Global Alzheimer’s Disease Diagnostic Market:
Some of the key players in this market are: Eli Lilly and Company (UK), TauRx (Republic of Singapore), Alector LLC (US), Accera, Inc. (US), Treventis Corporation (US), Neuro-Bio Ltd (UK), Cognition Therapeutics Inc. (US) and others.

Segments:

Global Alzheimer’s Disease Diagnostic Market has been segmented on the basis of type which comprises of early-onset Alzheimer's disease, late-onset Alzheimer's disease, familial Alzheimer's disease and more. On the basis of diagnostic tests; the market is segmented into genetic testing, neurological exam, mini-mental state exam (MMSE), brain imaging and others. On the basis of end users; the market is segmented into clinics, hospitals, diagnostic centers and others.